Nearly 2 million Americans suffer from schizophrenia, which is considered the most chronic and disabling of the severe mental disorders. In addition to psychotic symptoms, cognitive deficits, and social impairments, persons with schizophrenia are faced with multiple barriers to the achievement of optimal health. Psychiatric nurses must assess physical and psychological risk factors, monitor medication responses and side effects, and provide health promotion strategies for persons with schizophrenia. After providing a brief summary of the diagnostic criteria and clinical features of schizophrenia, this article reviews medication management with atypical agents and serious drug reactions.
Get full access to this article
View all access options for this article.
References
1.
Allen, R.M., & Flemenbaum, A. (1979). The effect of amantadine HCl on haloperidol-induced striatal dopamine neuron hypersensitivity. Biological Psychiatry, 14, 541-544.
2.
Alpert, M., Friedhoff, A.J., Marcos, L.R., & Diamond, F. (1978). Paradoxical reaction to L-dopa in schizophrenic patients. American Journal of Psychiatry, 135, 1329-1332.
3.
American Psychiatric Association. (2002). Practice guidelines for the treatment of psychiatric disorders (4th ed., text revision). Washington, DC: Author.
4.
American Psychiatric Association. (2000a). Diagnostic and statistical manual of mental disorders. Washington, DC: Author.
5.
American Psychiatric Association. (2000b). Handbook of psychiatric measures. Washington, DC: Author.
6.
Arvanitis, L.A., & Miller, B.G. (1997). Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. Biological Psychiatry, 42, 233-246.
7.
Ayd, F.J. (1961). A survey of drug induced extrapyramidal reactions. Journal of the American Medical Association, 75, 1054-1060.
8.
Beasley, C.M. Jr., Tollefson, G., Tran, P., Satterlee, W., Sanger, T., & Hamilton, S. (1996). Olanzapine versus placebo and haloperidol: Acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology, 14, 111-123.
9.
Bottlender, R., Jager, M., Hofschuster, E., Dobmeier, P., & Moller, H.J. (2002). Neuroleptic malignant syndrome due to atypical neuroleptics: Three episodes in one patient. Pharmacopsychiatry, 35, 119-121.
10.
Braude, W.M., Barnes, T.R.E., & Gore, S.M. (1983). Clinical characteristics of akathisia: A systematic investigation of acute psychiatric inpatient admissions. British Journal of Psychiatry, 143, 139-150.
11.
Breier, B.A., Buchanan, R.W., Irish, D., & Carpenter, W.T. Jr. (1993). Clozapine treatment of outpatients with schizophrenia: Outcome and long-term response pattern. Hospital and Community Psychiatry, 44, 1145-1149.
12.
Carnahan, R.M., Lund, B.C., & Perry, P.J. (2001). Ziprasidone, a new a typical antipsychotic drug. Pharmacotherapy, 21, 717-730.
13.
Carson, W.H., McQuade, R.D., Ali, M., Saha, A.R., Dunbar, G.C., & Ingenito, G. (2002). A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophrenia Research, 49(Suppl. 1), 221.
Chakos, M.H., Mayerhoff, D.I., Loebel, A.D., Alvir, J.M., & Lieberman, J.A (1992). Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. Psychopharmacology Bulletin, 28, 81-86.
16.
Chouinard, G., Jones, B., Remington, G., Bloom, D., Addington, D., MacEwan, W., et al. (1993). A Canadian multicenter placebo controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 25-49.
17.
Csernansky, J.G., Mahmoud, R., & Brenner, R. (2002). Risperidone reduced the risk of relapse in outpatient schizophrenia and schizoaffective disorder. Evidence-Based Mental Health, 5, 77.
18.
Cutler, A.J. (2002 May). Optimizing management of schizophrenia: Bridging the gap between clinical research and real-world clinical practice. In D.R. Weinberger (Chair), Advances in the Treatment of Psychosis: Minimizing the Burden of Disease. Symposium conducted at the meeting of the American Psychiatric Association, Philadelphia, PA.
19.
Davis, J.M., & Chen, N. (2001). The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: Combined results of the North American and international trials. Journal of Clinical Psychiatry, 62, 757-771.
20.
Dinakar, H.S., Sobel, R.N., Bopp, J.H., Daniels, A., & Mauro, S. (2002). Efficacy of olanzapine and risperidone for treatment of refractory schizophrenia among long-stay state hospital patients. Psychiatric Services, 53, 755-777.
21.
Emsley, R.A., Raniwalla, J., Bailey, P.J., & Jones, A.M. (2000). A comparison of the effects of quetiapine and haloperidol in schizophrenia patients with a history of and demonstrated partial response to conventional antipsychotic treatment. International Clinical Psychopharmacology, 15, 121-131.
22.
Eschweller, G.W., Bartels, M., Langle, G., Wild, B., Gaertner, I., & Nickola, M. (2002). Heart rate variability in the ECG trace of routine EEGs: Fast monitoring for the anticholinergic effects of clozapine and olanzapine? Pharmacopsychiatry, 35, 96-100.
Green, A.I., Patel, J.K., Goisman, R.M., Allison, D.B., & Blackburn, G. (2000). Weight gain from novel antipsychotic drugs: Need for action. General Hospital Psychiatry, 22, 224-235.
26.
Green, M.F., Marder, S.R., Glynn, S.M., McGurk, S.R., Wirshing, W.C., Wirshing, D.A., et al. (2002). The neurocognitive effects of low dose haloperidol: A 2-year comparison with risperidone. Biological Psychiatry, 51, 972-978.
27.
Guy, W. (1976). Assessment manual for psychopharmacology—revised (DHEW Publication No. ADM 76-338, pp. 534-537). Rockville, MD: U.S. Dept of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs.
28.
Harris, E.C., & Barraclough, B. (1998). Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. British Journal of Psychiatry, 173, 11-53.
29.
Hirsch, S.R., Kissling, W., Bauml, J., Power, A., & O’Connor, R. (2002). A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. Journal of Clinical Psychiatry, 63, 516-523.
30.
Janicak, P.G., Davis, J.M., Preskorn, S.H., & Ayd, F.J. Jr. (1993). Principles and practice of psychopharmacotherapy. Baltimore: Williams & Wilkins.
31.
Jordan, S., Koprivica, V., Chen, R., Tottori, K., Kikuchi, T., & Altar, C.A. (2002). The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. European Journal of Pharmacology, 441, 137-140.
32.
Kane, J.M., Carson, W.H., Saha, A.R., McQuade, R.D., Ingenito, G.C., Zimbroff, D.L., et al. (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizo affective disorder. Journal of Clinical Psychiatry, 63, 763-771.
33.
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1998). Clozapine for the treatment resistant schizophrenia: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
34.
King, D.J., Link, C.G.G., & Kowalcyk, B. (1998). A comparison of BID and TID dose regimens of quetiapine in the treatment of schizophrenia. Psychopharmacology, 137, 139-146.
35.
Kinon, B.J., Milton, D.R., & Stouffer, V.L. (1999, May). Effect of chronic olanzapine treatment on the course of presumptive TD. Paper presented at the meeting of the American Psychiatric Association, Washington, DC.
Lappa, A., Podesta, M., Capelli, O., Castagna, A., Di Placido, G, Alampi, D., et al. (2002). Successful treatment of a complicated case of NMS. Intensive Care Medicine, 28, 976-977.
38.
Lieberman, J.A., Saltz, B.L., Johns, C.A., Pollack, S., Borenstein, M., & Kane J. (1991). The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry, 158, 503-510.
39.
Lykouras, L., Agelopoulos, E., & Tzavellas, E. (2002). Improvement of TD following switch from neuroleptics to olanzapine. Progress in NeuroPsychopharmacology and Biological Psychiatry, 26, 815-817.
40.
Marder, S.R., & Meibach, R.C. (1994). Risperidone in the treatment of schizophrenia. American Journal of Psychiatry, 151, 825-835.
41.
Margolese, H.C., Chouinard, G., Beauclair, L., & Belanger, M.C. (2002). Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychopharmacology, 22, 347-352.
42.
McEvoy, J.P. (2002, May). The impact of safety and tolerability on patients’ satisfaction with therapy. In D.O. Perkins (Chair), Challenges and Opportunities in the Management of Psychotic Disorders. Symposium presented at the meeting of the American Psychiatric Association, Philadelphia, PA.
43.
Meltzer, H.Y. (1992). Treatment of the neuroleptic nonresponsive schizophrenic patient. Schizophrenia Bulletin, 18, 515-542.
44.
Meltzer, H.Y., Burnett, S., Bastani, B., & Ramirez, L.F. (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital and Community Psychiatry, 41, 892-897.
45.
Millan, M.J. (2000). Improving the treatment of schizophrenia: Focus on serotonin (5-HT)1A receptors. Journal of Pharmacology and Experimental Therapeutics, 295, 853-861.
46.
Oyen, W.J., Claessens, R.A., Raemaekers, J.M., DePauw, B.E., van der Meer, J.W., & Corstens, F.H. (1992). Diagnosing infection in febrile granulocytopenic patients with indium-III-labeled human immunoglobulin.. Journal of Clinical Oncology, 10, 61-68.
47.
Peuskens, J. (1995). Risperidone in the treatment of patients with chronic schizophrenia: A multinational, multicentre, double blind, parallel group study versus haloperodol. British Journal of Psychiatry, 166, 712-726.
48.
Peuskens, J., & Link, C.G. (1997). A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatrica Scandanavica, 96, 265-273.
49.
Reeves, R.R., Mack, J.E., & Beddingfield, J.J. (2002). Neurotoxic syndrome associated with risperidone and fluvoxamine. Annals of Pharmacotherapy, 36, 440-443.
50.
Remington, G., & Kapur, S. (1999). D2 and 5-HT2 receptor effects of antipsychotics: Bridging basic and clinical findings using PET. Journal of Clinical Psychiatry, 60(Suppl. 10), 15-19.
51.
Rosenquist, K.J., Walker, S.S., & Ghaemi, S.N. (2002). Tardive dyskinesia and ziprasidone. American Journal of Psychiatry, 159, 1436.
52.
Safferman, A., Lieberman, J.A., Kane, J.M., Szymanski, S., & Kinon, B. (1991). Update on the clinical efficacy and side effects of clozapine. Schizophrenia Bulletin, 17, 247-261.
53.
Saha, A.R., Carson, W.H., Ali, M.W., Dunbar, G.C., & Ingenito, G. (2001). Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Western Journal of Biological Psychiatry, 2(Suppl. 1), 305S.
54.
Schauwecker, D.S. (2002). Imaging infection in patients with agranulocytosis. Journal of Nuclear Medicine, 43, 925-927.
55.
Schooler, N.R., & Kane, J.M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486-487.
56.
Shopsin, N.B., Klein, H., Aaronson, M., & Collora, M. (1979). Clozapine, chlorpromazine and placebo in newly hospitalized, acutely schizophrenic patients: A controlled, double blind comparison. Archives of General Psychiatry, 36, 657-664.
57.
Spina, E., Avenoso, A., Scordo, M.G., Ancione, M., Madia, A., Gatti, G., et al. (2002). Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: A clinically relevant pharmacokinetic drug interaction. Journal of Clinical Psychopharmacology, 22, 419-423.
58.
Stahl, S.M. (2001). Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics: Part 2, Illustrating their mechanism of action. Journal of Clinical Psychiatry, 62, 824-841.
59.
Stimmel, G.L., Gutierrez, M.A., & Lee, V. (2002). Ziprasidone: An atypical antipsychotic drug for the treatment of schizophrenia. Clinical Therapeutics, 24(1), 21-37.
60.
Szymanski, S., Masiar, S., Mayerhoff, D., Loebel, A., Geisler, S., Pollack, S., et al. (1994). Clozapine response in treatment-refractory first episode schizophrenia. Biological Psychiatry, 35, 278-280.
61.
Taylor, J. (2002). Development of a screening tool to assess risk of tardive dyskinesia. British Journal of Nursing, 11, 374-378.
Tollefson, G.D, Beasley, C.M., Tran, P.V., Street, J.S., Krueger, J.A., Tamura, R.N., et al. (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. American Journal of Psychiatry, 154, 457-465.
64.
VanPutten, T., & May, P.R.A. (1978). Akinetic depression in schizophrenia. Archives of General Psychiatry, 35, 1101-1107.
65.
Yang, S., & McNeely, M.J. (2002). Rhabdomyolysis, pancreatitis and hyperglycemia with ziprasidone. American Journal of Psychiatry, 159, 1435.
66.
Yeung, P.P., Carson, W.H., Saha, A.R., McQuade, R.D., Ali, M.W., String-fellow, J.C., & Ingenito, G. (2001). Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: Results of a placebo-controlled trial with risperidone. European Neuropsychopharmacology, 3(Suppl. 11), S241.
67.
Young, N.S. (1994). Agranulocytosis. Journal of the American Medical Association, 271, 935-938.
